Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunotherapy of Brain Tumors.
Dutoit V, Migliorini D, Walker PR, Dietrich PY. Dutoit V, et al. Among authors: migliorini d. Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376741 Review.
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, Maloney E, Brem S, Lustig RA, Kurtz G, Alonso-Basanta M, Bonté PE, Goudot C, Richer W, Piaggio E, Kothari S, Guyonnet L, Guerin CL, Waterfall JJ, Mohan S, Hwang WT, Tang OY, Logun M, Bhattacharyya M, Markowitz K, Delman D, Marshall A, Wherry EJ, Amigorena S, Beatty GL, Brogdon JL, Hexner E, Migliorini D, Alanio C, O'Rourke DM. Bagley SJ, et al. Among authors: migliorini d. Nat Cancer. 2024 Mar;5(3):517-531. doi: 10.1038/s43018-023-00709-6. Epub 2024 Jan 12. Nat Cancer. 2024. PMID: 38216766 Clinical Trial.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Johnson Z, Tarantelli C, Civanelli E, Cascione L, Spriano F, Fraser A, Shah P, Nomanbhoy T, Napoli S, Rinaldi A, Niewola-Staszkowska K, Lahn M, Perrin D, Wenes M, Migliorini D, Bertoni F, van der Veen L, Di Conza G. Johnson Z, et al. Among authors: migliorini d. Cancer Res Commun. 2023 Apr 14;3(4):576-591. doi: 10.1158/2767-9764.CRC-22-0477. eCollection 2023 Apr. Cancer Res Commun. 2023. PMID: 37066023 Free PMC article.
ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?
Haemmerli J, Sveikata L, Nouri A, May A, Egervari K, Freyschlag C, Lobrinus JA, Migliorini D, Momjian S, Sanda N, Schaller K, Tran S, Yeung J, Bijlenga P. Haemmerli J, et al. Among authors: migliorini d. BMJ Health Care Inform. 2023 Jun;30(1):e100775. doi: 10.1136/bmjhci-2023-100775. BMJ Health Care Inform. 2023. PMID: 37399360 Free PMC article.
[Cerebral lymphoma: a classic presentation?].
Nemitz I, Migliorini D, Dietrich PY. Nemitz I, et al. Among authors: migliorini d. Rev Med Suisse. 2015 Feb 4;11(460):371-3. Rev Med Suisse. 2015. PMID: 25854049 French. No abstract available.
The CD40/CD40L axis in glioma progression and therapy.
Walker PR, Migliorini D. Walker PR, et al. Among authors: migliorini d. Neuro Oncol. 2015 Nov;17(11):1428-30. doi: 10.1093/neuonc/nov138. Epub 2015 Jul 22. Neuro Oncol. 2015. PMID: 26206773 Free PMC article. No abstract available.
108 results